National Cancer Center of South Korea Selects Velos to Support Clinical Trials Conducted Throughout Country

Thursday, August 16, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

FREMONT, Calif., Aug. 15 Velos, Inc., the recognizedleader and trusted resource for U.S. clinical trial management informationsystems, and the nation of South Korea through its National Cancer Center,have agreed to deploy Velos eResearch to support cancer research throughoutSouth Korea. The National Cancer Center of South Korea is a governmentresearch sponsor equivalent to the National Cancer Institute in the UnitedStates and serves a large population about the size of California.

"We are very pleased to launch the Velos relationship," said Dr.Keun-Young Yoo, president of the National Cancer Center, Korea. "With VeloseResearch, we are fulfilling an important mission for the cancer researchcommunity of South Korea by establishing a state-of-the-art clinical trialcollaboration and execution system infrastructure. Velos, with its advancedtechnology, will support efficient, high quality multi-site collaboration andrapid deployment capabilities for cancer research throughout South Korea.This, in turn, brings unique advantages for future, large scale, cancerclinical research programs in South Korea."

Velos eResearch will fundamentally improve the way data is collected,organized and shared among research sites, patients, the National CancerCenter and other research sponsors. An advanced, pure Internet technologyplatform with Velos will enable all to collaborate in a secure and integratedsystem. With Velos, investigator sites for South Korean cancer trials willhave an exceptional product to address their research-related clinical,administrative and financial needs while also addressing the needs of theNational Cancer Center and other sponsors.

"We are honored to work with the nation of South Korea and to be part ofthe forward-thinking approach of the National Cancer Center," stated John S.McIlwain, CEO of Velos, Inc. "This is precisely the Velos model: large scale,multi-enterprise research collaboration with a focus on addressing theinformation and research needs of both investigators and sponsors. TheNational Cancer Center of South Korea is well-positioned to harvest Velosadvantages and implement a secure, high quality, and cost-effectiveinformation platform clinical research."

"With Velos eResearch, we will have leadership system infrastructure and acohesive information network in place for cancer clinical research in SouthKorea," continued Dr. Keun-Young Yoo. "Velos addresses the information andregulatory needs of pharmaceutical sponsors while also robustly serving theinformation needs of investigators and sites. These capabilities positionSouth Korea to be especially productive and reliable in clinical researchexecution."

Velos eResearch is already widely used and highly regarded at top cancerresearch programs in the U.S. Velos customers receive approximately 35percent of extramural grants from the National Cancer Institute. Velos alsosupports clinical research in over 40 other medical specializations and counts22 top 25 academic medical centers and research institutions as customers(source: U.S. News and World Report 2006 Best Hospitals Survey). Through itsVelos partnership, the National Cancer Center further strengthens its positionfor collaboration with overseas partners.

About the National Cancer Center of South Korea

Founded in 2000 as a government-funded organization, the National CancerCenter (NCC) of South Korea is playing an essential role as the nationalcenter in the fight against cancer through research, medical care, educationand training. As a think-tank for cancer control policy research, the centeralso advises the Korean government on cancer control issues such as providingpolicy options for formulating, implementing and evaluating national cancercontrol programs. The NCC hospital, one of its three major functions,accommodates approximately 1,200 outpatients a day, having a capacity of 500be

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store